Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase 660,000 Ordinary Shares

John Furey, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 660,000 ordinary shares on July 1, 2024.

Summary

• On July 1, 2024, John Furey, a director of Adaptimmune Therapeutics PLC, filed a Form 4 indicating a change in beneficial ownership.
• Furey acquired options to purchase 660,000 ordinary shares of Adaptimmune Therapeutics.
• The exercise price of these options is $0.16, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Furey directly owns options to purchase 660,000 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring options generally signals confidence, but it's a routine transaction.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates